ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
about
Comparison of the safety and pharmacokinetics of ST-246® after i.v. infusion or oral administration in mice, rabbits and monkeysTherapy and long-term prophylaxis of vaccinia virus respiratory infections in mice with an adenovirus-vectored interferon alpha (mDEF201)Modeling the Effect of Herd Immunity and Contagiousness in Mitigating a Smallpox Outbreak.Antibody inhibition of a viral type 1 interferon decoy receptor cures a viral disease by restoring interferon signaling in the liver.Efficacy of ST-246 versus lethal poxvirus challenge in immunodeficient miceExperimental infection of cynomolgus macaques (Macaca fascicularis) with aerosolized monkeypox virus.A protein-based smallpox vaccine protects non-human primates from a lethal monkeypox virus challenge.Use of the Aerosol Rabbitpox Virus Model for Evaluation of Anti-Poxvirus Agents.Impact of ST-246® on ACAM2000™ smallpox vaccine reactogenicity, immunogenicity, and protective efficacy in immunodeficient mice.Pharmacokinetics and interspecies allometric scaling of ST-246, an oral antiviral therapeutic for treatment of orthopoxvirus infection.Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge.A novel respiratory model of infection with monkeypox virus in cynomolgus macaques.Development of the small-molecule antiviral ST-246 as a smallpox therapeutic.Cowpox virus infection of cynomolgus macaques as a model of hemorrhagic smallpox.Development of ST-246® for Treatment of Poxvirus Infections.Utilizing diversity-oriented synthesis in antimicrobial drug discovery.Small particle aerosol inoculation of cowpox Brighton Red in rhesus monkeys results in a severe respiratory disease.Sequence of pathogenic events in cynomolgus macaques infected with aerosolized monkeypox virus.Susceptibility of Marmosets (Callithrix jacchus) to Monkeypox Virus: A Low Dose Prospective Model for Monkeypox and Smallpox Disease.Treatment with the smallpox antiviral tecovirimat (ST-246) alone or in combination with ACAM2000 vaccination is effective as a postsymptomatic therapy for monkeypox virus infection.In vitro inhibition of monkeypox virus production and spread by Interferon-β.Safety and pharmacokinetics of the anti-orthopoxvirus compound ST-246 following a single daily oral dose for 14 days in human volunteers.Comparative pathology of smallpox and monkeypox in man and macaques.Unusual features of vaccinia virus extracellular virion form neutralization resistance revealed in human antibody responses to the smallpox vaccine.Pharmacokinetic and pharmacodynamic modeling to determine the dose of ST-246 to protect against smallpox in humans.Assessment of the protective effect of Imvamune and Acam2000 vaccines against aerosolized monkeypox virus in cynomolgus macaques.Orthopoxvirus targets for the development of new antiviral agents.Efficacy of tecovirimat (ST-246) in nonhuman primates infected with variola virus (Smallpox).ST-246 inhibits in vivo poxvirus dissemination, virus shedding, and systemic disease manifestationOrthopoxvirus inhibitors that are active in animal models: an update from 2008 to 2012.Animal models of orthopoxvirus infection.A review of experimental and natural infections of animals with monkeypox virus between 1958 and 2012.Identification of protein-protein interaction inhibitors targeting vaccinia virus processivity factor for development of antiviral agents.ST-246 is a key antiviral to inhibit the viral F13L phospholipase, one of the essential proteins for orthopoxvirus wrapping.Identification of a pyridopyrimidinone inhibitor of orthopoxviruses from a diversity-oriented synthesis libraryUsing the Ground Squirrel (Marmota bobak) as an Animal Model to Assess Monkeypox Drug Efficacy.The Possibility of Using the ICR Mouse as an Animal Model to Assess Antimonkeypox Drug Efficacy.Infection of cynomolgus macaques with a recombinant monkeypox virus encoding green fluorescent protein.Suppression of Poxvirus Replication by Resveratrol.Validation of a pan-orthopox real-time PCR assay for the detection and quantification of viral genomes from nonhuman primate blood.
P2860
Q28741437-341F18AC-0BBF-40F1-A7AB-D21BDE847562Q28743894-715A668C-AE86-46ED-B908-42C36C300CDCQ30205740-38B1F07A-9172-4AC8-875B-4ED7E91189AAQ31045190-883B52CE-3DD8-453A-84B9-C071A09ABB20Q33639966-F832AE4D-E4E3-4DC8-8690-611C6C714193Q33700318-9C8D9FE6-37E2-4E54-93FB-EC70B3F47B04Q34126697-54835B3F-0362-4AF2-A25F-C38090549436Q34196187-D5B655D1-0100-4C2D-9F20-B329FB8A70B7Q34502253-AF13550E-4F8A-4DBE-9908-DFC43F251FF8Q34700352-EFA917D1-17AF-4768-9B08-CA44C7099055Q34910424-1D4D8F08-7ACC-478B-92FD-23B1A720DE6FQ35076685-5D4ECF7C-7C52-4F1A-B0BE-5655F65C5666Q35152092-D18E0531-E913-4FA0-AFF7-CC84B373852EQ35189550-CEBAC40E-5F0D-4ECB-A42B-7F4ABAE850AEQ35260385-AAF156B0-EC78-4B8E-8819-FCAA65772920Q35510383-BD64B94B-0F63-48B7-83A6-0D2D81921589Q35578840-40B506E5-DF5C-4742-A902-05250DA3818FQ35640911-1B4F74C0-86FC-4D70-8359-EF3BC0C07AF6Q35683735-C03C98B5-FED7-4205-A6C6-E1E8EF4A7E1CQ35745996-FD4BDC4D-D85A-4087-B034-01B414C0B74EQ35772104-C351073A-FC0A-4E1D-A4A6-B0FB5251CE3AQ36172531-AE30154E-511D-4AA2-8C75-227DB6ABEBE3Q36400333-02ED6F2D-CC3C-4981-A543-5324D1D11F10Q36559797-CF0FCB18-FBD2-48FD-9E6D-49B9F4FA4F25Q36667010-BC3B464D-358E-4F04-812A-3DD6934592D0Q36978610-827411D4-5E18-4438-9343-FCD31285CFDEQ37173398-4DC69822-4796-427E-9DB7-B5F176258B22Q37335688-6099DD6F-2D24-4520-9FB9-74BDA37E0621Q37450819-0045BDAE-ABA9-4826-A4BA-CDBFAE4B4208Q37593480-50388819-FBCB-4097-B51F-DAE674B6BFCEQ37777545-0C48BBBB-055B-42F5-BD10-3F5238F50019Q38102696-13EFA7DE-2974-4187-B82C-52037D15529EQ38726418-719D6382-BA92-4B93-972E-8F7BE3ADD9DEQ39046951-6BCA3896-1578-4E3B-8070-F880A1C84EA8Q39420959-87BE67D4-45C6-4057-9D6A-8D72CB0B90C5Q41257119-B0372013-1AFE-4FDB-9CA7-93C57D9C4C00Q41536989-C6A5C027-DE67-45BD-8A44-9BADBBDA438FQ45364407-3A06465A-0C94-4655-BFAF-2934FB846BB7Q47107948-E4C0B047-D26C-47EF-BBB9-248D939911AAQ47227051-F9CACA5C-478B-4AE3-BD38-CE48D4816389
P2860
ST-246 antiviral efficacy in a nonhuman primate monkeypox model: determination of the minimal effective dose and human dose justification.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 February 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
ST-246 antiviral efficacy in a ...... and human dose justification.
@en
ST-246 antiviral efficacy in a ...... and human dose justification.
@nl
type
label
ST-246 antiviral efficacy in a ...... and human dose justification.
@en
ST-246 antiviral efficacy in a ...... and human dose justification.
@nl
prefLabel
ST-246 antiviral efficacy in a ...... and human dose justification.
@en
ST-246 antiviral efficacy in a ...... and human dose justification.
@nl
P2093
P2860
P356
P1476
ST-246 antiviral efficacy in a ...... and human dose justification.
@en
P2093
Adams Amantana
Annie Frimm
Arthur Goff
Carly Wlazlowski
Chelsea M Byrd
Dennis E Hruby
Eric Mucker
Jarasvech Chinsangaram
Jennifer Chapman
John Huggins
P2860
P304
P356
10.1128/AAC.01596-08
P407
P577
2009-02-17T00:00:00Z